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Abstract 
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone with well-established 
glucose-lowering activity. The  in vitro  and  in vivo actions of natural putative 
secretagogues of GLP-1 were investigated. The acute GLP-1 releasing activity 
of olive leaf extract (OLE), glutamine (GLN), alpha casein (ACAS), beta casein 
(BCAS) and chlorogenic acid (CGA) were assessed in STC-1 cells and 
C57BL/6 mice. All compounds except ACAS significantly increased  acute  in 
vitro GLP-1 secretion (66-386%; P<0.05–0.001). Oral gavage of OLE and GLN 
modestly increased plasma GLP-1 concentrations (48% and 41%, respectively), 
but did not lower glycaemic excursions. OLE and GLN are potent stimulators of 
GLP-1 secretion both in vitro and in vivo and chronic studies should assess 
their suitability as nutritional therapies for type 2 diabetes. 
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Introduction 
Glucagon-like peptide-1 (GLP-1) is an incretin hormone primarily produced in the entero-
endocrine L-cells of the distal intestine, and physiologically it is secreted in response to 616  E. P. Rafferty et al.:   
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nutrient ingestion [1]. GLP-1 is an attractive therapeutic target for type 2 diabetes because 
of its important actions, including stimulation of insulin biosynthesis and secretion, 
inhibition of glucagon secretion, inhibition of gastric emptying and acid secretion, reduction 
of food intake, and expansion of beta-cell mass in the pancreas (see review) [1]. A number 
of anti-diabetic drugs are now clinically available which act by mimicking or enhancing 
GLP-1 action, and a new recent focus of research is the identification of compounds which 
stimulate intestinal secretion of GLP-1. This study investigated the in vitro  and  in vivo 
effects of some natural putative sources of GLP-1-releasing activity.  
Extracts from olive leaves are presumed to stimulate GLP-1 secretion due to a naturally 
occurring compound called oleanoic acid—an activator of TGR5 receptors which are asso-
ciated with the secretion of GLP-1 [2]. Glutamine is an amino acid which has been demon-
strated to stimulate GLP-1 secretion in vitro and in vivo [3, 4]. Chlorogenic acid, a phenol 
compound naturally occurring in coffee, has been linked to GLP-1 secretion and reduced 
risk of type 2 diabetes [5, 6]. Similarly, the milk protein casein has been demonstrated to 
stimulate GLP-1 secretion in NCI-H716 cells [7]. In this study we tested the acute secre-
tory activity of olive leaf extract (OLE), glutamine (GLN), chlorogenic acid (CGA) alpha-ca-
sein (ACAS) and beta-casein (BCAS) in STC-1 cells and went on to assess in vivo effects 
by measurement of responses in mice following an oral glucose tolerance test (OGTT). 
Results and Discussion 
With the exception of ACAS all of the putative secretagogues significantly increased acute 
GLP-1 secretion compared with vehicle control; and ACAS was not selected for in vivo 
studies. OLE, GLN, BCAS and CGA significantly increased GLP-1 secretion 66%, 236%, 
180% and 386%, respectively (Figure 1A; P<0.01–0.001). Interestingly, GLN and CGA 
also led to significant increases (Figure 1B; 227% and 583%, respectively) in cellular 
GLP-1 content over the 72h incubation period indicating that these compounds may 
increase proglucagon gene expression or GLP-1 biosynthesis. Increases in plasma GLP-1 
secretion where observed for OLE and GLN (Figure 2C; 48% and 41%, respectively), but 
surprisingly none of the putative GLP-1 secretagogues reduced AUC values for glucose 
during OGTTs (Figure 2B).  
Type 2 diabetic patients consuming GLN (30g) exhibited significantly higher circulating 
levels of GLP-1, as well as GIP and insulin, but it is as yet unclear whether GLN improves 
glycaemic control [4]. Here, we have demonstrated a consistent effect of GLN in stimulat-
ing GLP-1 both in vitro and in vivo. However, during glucose challenge conditions GLP-1 
response of GLN did not lead to acute glucose lowering. Casein has previously been 
reported to stimulate GLP-1 secretion in vitro [7, 10]. Casein protein encompasses two 
protein sub-types: alpha and beta. Our in vitro studies indicate that BCAS has greater 
GLP-1 secretory activity than ACAS. Meal-related challenge of human volunteers with a 
diet containing 10% or 25% casein demonstrates that compared with other protein sources 
casein is not as important for eliciting GLP-1 secretion [11]. This study is in good agree-
ment finding no significant alteration in plasma GLP-1 levels following oral administration 
of BCAS. CGA was the only compound tested which altered OGTT responses, however it 
rather unexpectedly appeared to increase glycaemic excursions rather than reduce them. 
A previous study in humans reported that compared with placebo 1g of CGA reduced early 
glucose responses but not the overall AUC values during the OGTT [12]; furthermore no 
changes in plasma GLP-1 levels were recorded [13]. We also did not find any evidence 
that CGA alters GLP-1 concentrations during OGTT.   In Vitro and In Vivo Effects of Putative GLP-1 Secretagogues  617 
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Fig. 1.   Effects of natural putative GLP-1 secretagogues on GLP-1 secretion and 
cellular GLP-1 content in STC-1 cells. (A) STC-1 cells were incubated for 3h 
with OLE, GLN, ACAS, BCAS or CGA before determination of GLP-1 secretion. 
(B) Cellular GLP-1 content of STC-1 cells following 72 h incubation with OLE, 
GLN, ACAS, BCAS or CGA, or vehicle control (media). GLP-1 was removed 
from cells using an acid/ethanol extraction method and CCK concentrations 
were determined by radioimmunoassay. Results are mean ± SEM (n=6). 
*P<0.05, **P<0.01 and ***P<0.001 compared with control, ns- not significant. 
Experiments were repeated on 2 occasions.  
Other studies have demonstrated that continued consumption of natural putative GLP-1 
secretagogues over a prolonged period improves hyperglycaemia associated with 
diabetes [2, 14]. This study demonstrates that on a cellular level OLE, GLN, BCAS and 
CGN potently stimulate GLP-1 secretion, but in vivo studies only indicate modest rises in 
plasma GLP-1 concentrations for OLE and GLN. Therefore, the amount of GLP-1 released 
by these putative GLP-1 secretagogues is perhaps not sufficient to counteract a rapid rise 
in glucose levels following an oral glucose challenge. In can be concluded that the 
potential benefits of these GLP-1 secretagogues are not likely to be realised over an acute 
period, and chronic studies in diabetic animal models should be undertaken to assess their 
usefulness as nutritional therapies for type 2 diabetes.  
Experimental 
OLE was prepared by dichloromethane extraction of powdered olive leaves (Olea 
europoaea) as previously described [2]. Briefly, dried powdered olive leaves (10g) (Olea 
europaea) were extracted with dichloromethane (100 mL) using soxhlet apparatus. Solvent 
was evaporated under reduced pressure and the remaining residue was weighed and 
stored at −20˚C (for more details see [2]). GLN (>99% purity), CGA (>95% purity), ACAS 
(>70% purity) and BCAS (>98% purity) were purchased from Sigma (Poole, Dorset, UK). 
STC-1 cells were obtained from from Dr D Hanahan  (University of California, San 
Francisco, CA) and cultured as previously described [8, 9]. Briefly, cells were cultured in 
DMEM containing 4.5 g/l D-glucose, (GlutaMAX, GIBCO, Paisley, UK) supplemented with 
17.5% foetal bovine serum (FBS), 100U/ml penicillin and 100mg/L streptomycin and 
incubated in a 5% CO2 humidified atmosphere at 37°C. Cells underwent passage upon 
reaching 80–90% confluence and were used between passage numbers 15–50. 618  E. P. Rafferty et al.:   
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Fig. 2.   Effects of oral OLE, GLN, BCAS, and CGA on glucose tolerance and GLP-1 
concentrations in mice. (A) OLE (100mg/kg), GLN (1g/kg), BCAS (0.5 g/kg), or 
CGA (5 mg/kg) were orally gavaged with glucose (18 mmol/kg) to mice and 
glucose responses were monitored at 0, 15, 30, 60 and 105 min. (B) 
Incremental areas under plasma glucose curves (∆AUC0-105) were calculated 
using a computer-generated program employing the trapezoidal rule with 
baseline subtraction. Area under the curve (AUC) values data were compared 
using repeated measures one-way Analysis of Variation (ANOVA) followed by 
the Student-Newman-Keuls post hoc test. (C) Mice were orally gavaged with 
glucose (18mmol/kg) or glucose in combination with putative GLP-1 
secretagogues and after 30 min mice were sacrificed, blood obtained by cardiac 
puncture and GLP-1 concentrations were determined in plasma. Results are 
mean ± SEM (n=6); *P<0.05 compared with glucose alone; ns- not significant. 
For acute GLP-1 secretion approximately 2x10
6  cells (n=6) were seeded into 12 well 
plates and incubated for 18h at 37°C. Media was removed, the cells were washed with 
HEPES buffer and then underwent 60 min pre-incubation with buffer (20mM HEPES, 10 
mM glucose, 140nM NaCl, 4.5mM KCl, 1.2mM CaCl2, 1.2mM MgCl2). Buffer was aspirated 
off and cells were incubated for 3h with 400µl of vehicle or OLE (1mg/ml), GLN (40 mM), 
ACAS (1 mg/ml), BCAS (1 mg/ml), and CGA (40 mM). The responsiveness of cells was 
verified by conducting test incubations with a mixture of fatty acids as a positive control 
(data not shown). After the test period 350µl of the incubation solution was removed to a   In Vitro and In Vivo Effects of Putative GLP-1 Secretagogues  619 
Sci Pharm. 2011; 79: 615–621 
separate tube, placed on ice and centrifuged (900g, 5 min) to remove any cellular debris. 
The supernatant was collected and stored at −80°C prior to analysis by GLP-1 
radioimmunoassay. For cellular GLP-1 content STC-1 cells (1.5 x 10
6) were seeded into 6 
well plates and cultured overnight at 37°C in a humidified atmosphere of 5% CO2. Media 
was removed and fresh media or secretagogue supplemented media was added. Media 
was removed and replaced with fresh supplemented media every 24h until an incubation 
period of 72h was reached. Media was then removed, cells were washed and GLP-1 was 
extracted by the addition of acid/ethanol (1.5% HCl (v/v): 75% ethanol (v/v): 23.5% H2O 
(v/v)) and incubated overnight at 4°C. Acid/ethanol solutions were removed, centrifuged 
(900g, 5 min) to remove cellular debris, and the ethanol evaporated off using a SpeedVac 
sample concentrator (Genevac, Ipswich, UK). Samples were reconstituted in buffer prior to 
radioimmunoassay. GLP-1 was measured using an in-house fully optimised radioimmuno-
assay which used a GLP-1(7-36)amide standard curve (Molar IC50 = 1.6x10
11; R
2 = 0.99) 
and employed anti-rabbit IgG Sac-Cel (IDS, Boldon, UK), and a polyclonal rabbit antibody 
with no cross-reactivity for glucagon or GIP.  
OGTT studies involved  16h-fasted  C57BL/6  mice receiving oral gavage of glucose 
(18 mmol/kg), or glucose in combination with OLE (100mg/kg), GLN (1g/kg), BCAS 
(0.5 g/kg), or CGA (5 mg/kg). For studies measuring plasma GLP-1, mice were sacrificed 
in a carbon dioxide atmosphere 30 min post-administration and blood samples taken by 
cardiac puncture using a heparinised syringe. Blood was centrifuged for 30 seconds at 
13000g (IEC Micromax RF) and plasma stored at −80˚C prior to analysis. 
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